Introduction {#s1}
============

Cancer development involves accumulation of genetic changes that leads to the malignant transformation of normal cells. Mutations induced by DNA-damaging agents are closely associated with specialized translesion synthesis (TLS) DNA polymerases ([@CIT0001],[@CIT0002]). Many TLS polymerases belong to the Y-family of DNA polymerases, which can replicate damaged nucleotides in an error-prone as well as error-free fashion ([@CIT0002],[@CIT0003]). Four individual Y-family polymerases have been identified in vertebrates: Pol η, Pol ι, Pol κ and Rev1 ([@CIT0001]). Mutations in genes encoding these polymerases may increase susceptibility to mutagenesis and cancer ([@CIT0005]), as has been demonstrated for Pol η ([@CIT0010],[@CIT0011]).

Rev1 is a key factor in error-prone TLS ([@CIT0012]). Although Rev1 is a deoxycytidyltransferase that incorporates deoxycytosines opposite structurally diverse damaged nucleotides ([@CIT0013]), its most important function in error-prone TLS is regulatory rather than catalytic ([@CIT0001],[@CIT0002],[@CIT0014],[@CIT0019]). Deletion of Rev1 results in sensitivity to a wide range of DNA-damaging agents, such as UV light, hydrogen peroxide, cisplatin and X-rays ([@CIT0020]). DNA damage-induced cytotoxicity and mutagenicity depend on the expression level of hREV1 ([@CIT0024]).

Owing to its importance in the response to DNA damage, hREV1 has attracted considerable interest in the field of cancer research. Mutations in *hREV1* have been detected in a minority of tumors ([@CIT0029]), and single-nucleotide polymorphisms in the gene have been linked to various types of human cancer ([@CIT0030]). As with other TLS polymerases, upregulation of hREV1 is associated with the pathogenesis of human glioma ([@CIT0035],[@CIT0036]). These data imply that dysregulation of cellular Rev1 levels is a critical step in *in vivo* tumorigenesis. To date, however, this hypothesis has not been directly evaluated. In addition, details of the mechanism by which Rev1 affects carcinogenesis *in vivo* are not available. In this study, we investigated the effect of deregulated Rev1 expression on susceptibility to tumorigenesis in a new transgenic mouse model.

Materials and methods {#s2}
=====================

Generation of *Rev1* transgenic mice {#s3}
------------------------------------

A DNA fragment containing the mouse metallothionein promoter (MT-1), *Rev1* cDNA, and a simian virus 40 polyadenylation (SV40 polyA) signal were used to generate transgenic mice by pronuclear injection of C57BL/6 zygotes. Transgenic founders were identified by PCR and Southern blotting of tail genomic DNA. Transgene-positive founders were bred with wild-type (Wt) C57BL/6N mice to establish independent lines. All mice were housed in compliance with the guidelines of the Institute of Laboratory Animal Science, Hiroshima University.

Real-time RT-PCR and quantitative real-time RT-PCR {#s4}
--------------------------------------------------

To determine the relative expression of *Rev1* in various tissues, total RNA was purified from various tissues and reverse transcribed into cDNA. To quantitate levels of *Rev1* mRNA expression in the small intestine, quantitative real-time RT-PCR was carried out on an Applied Biosystems 7500 Real-time PCR System (Applied Biosystems) using Absolute SYBR Green Mix. The expression level of *Rev1* mRNA was normalized against *Gapdh*, and all reactions were performed in triplicate.

Mice and tumor induction {#s5}
------------------------

Male C57BL/6N mice were purchased from Charles River (Hino, Japan). Starting at 3 weeks of age, *Rev1* Tg and normal C57BL/6N male mice were treated with 25 mM ZnSO~4~ in drinking water to induce transgenic Rev1 expression. Beginning at 6 weeks of age, the mice were injected intraperitoneally with *N*-methyl-*N*-nitrosourea (MNU) (SIGMA, Japan), 50 mg/kg of body weight, once per week for 2 weeks. Mice were observed daily until becoming moribund, and then sacrificed under anesthesia and necropsied. Concentration of hemoglobin (Hgb) in peripheral blood was measured using a PCE-310 hygrometer (ERMA). Tissue was collected from MNU-treated animals for weight measurements and histology.

Scoring and classification of intestinal tumors {#s6}
-----------------------------------------------

For macroscopic assessment of intestinal adenoma, mice were sacrificed 2 months after MNU treatment, and the small intestine was isolated. The small intestine was flushed with phosphate-buffered saline, opened longitudinally and examined using a binocular operation microscope. Tumors were counted following alkaline phosphatase staining.

Detection of mutations in the Ctnnb1 (β-catenin) gene {#s7}
-----------------------------------------------------

DNA was extracted from frozen intestinal adenoma using a DNA extraction kit. PCR primers were designed to amplify the region of the *Ctnnb1* gene encoding the consensus sequence for GSK-3β phosphorylation. The PCR products were purified and sequenced.

Quantitation of apoptosis *in vivo* {#s8}
-----------------------------------

At the indicated time points after injection, at least three mice were sacrificed. The small intestine was removed from each mouse, flushed with phosphate-buffered saline, and fixed in 10% formalin. Histological sections were prepared, and apoptosis was scored in intestinal crypts as reported previously ([@CIT0037]). At least 50 half-crypts were scored. TUNEL assays were performed using the *In Situ* Apoptosis Detection Kit (TaKaRa, Japan). Slides were counterstained with hematoxylin.

Cell culture and the establishment of stable cell lines {#s9}
-------------------------------------------------------

The human fibrosarcoma cell line HT1080 was purchased from the ATCC (no. CCL121). Once resuscitated, the line was authenticated through monitoring of cell morphology and karyotype. Cells were grown under standard conditions in MEM supplemented with fetal bovine serum and antibiotics. Cells were transfected with FuGENE HD transfection reagent (Roche, Japan). HT1080 T-REx cells that express hREV1 protein were generated by transfection with pcDNA4/TO (Thermo Fisher Scientific K. K., Japan) carrying the *hREV1* gene. Zeocin-resistant colonies were selected and screened for hREV1 protein by Western blotting. To induce hREV1, cells were incubated with 1 µg/ml tetracycline 24 h before experiments started.

Colony-formation assays {#s10}
-----------------------

Colony-formation assays were performed by seeding 300 cells in each of three 100 mm dishes. Twenty-four hours after seeding, cells were cultured with or without tetracycline to induce hREV1 expression for 24 h, and the indicated amounts of MNU were then added to the dishes. The medium was replaced 1 h later, and the cells were incubated for 8 days. Colonies were fixed, stained with crystal violet and counted.

HPRT assays {#s11}
-----------

HPRT mutants were selected, and mutation frequencies were determined according to published protocols. Cells were pre-selected for functional HPRT by expanding the cultures for 2 days in medium supplemented with 1× HAT, and then cultured for an additional 3 days. Growing cells were treated with or without MNU. The cells were maintained in logarithmic growth phase by replating until they underwent 4--7 population doublings for mutation expression. Mutant selection was performed by replating cells at 3 × 10^5^ cells/10 cm dish into medium containing 40 μM 6-thioguanine. Colony-forming efficiency at the time of selection was determined by plating 300 cells/10 cm dish without 6-thioguanine (three dishes for each condition).

Statistical analyses {#s12}
--------------------

Statistically significant differences and exact p values of comparisons between survival curves were determined using the Logrank (Mantel-Cox) test. In all other cases, *t*-tests (for two sets of data) or ANOVA analysis (for three or more sets of data) were performed using the StatMate III and GraphPad 6 software packages.

Results {#s13}
=======

Generation and characterization of *Rev1* Tg mice {#s14}
-------------------------------------------------

We generated *Rev1* transgenic mice (*Rev1* Tg) to determine whether overexpression of Rev1 would result in tumorigenesis. The metallothionein promoter 1 (MT-1) was used to achieve inducible *Rev1* expression (Supplementary Figure 1a, available at *Carcinogenesis* Online). Four founder mice were identified, three of which passed the transgene on to their offspring (Supplementary Figure 1b, available at *Carcinogenesis* Online). All of the resultant *Rev1* Tg mice were apparently normal regarding development, gross morphology, behavior and fertility, even when receiving ZnSO~4~ in drinking water; hence, data reported hereafter were obtained from mice treated with ZnSO~4~ as described in Materials and Methods. Expression of the transgene was examined in multiple organs obtained from the *Rev1* Tg T5 line, which expressed the highest level of the transgene. In male mice, which were used in the following experiments, *Rev1* was expressed at low levels in the liver and kidney, but at dramatically higher levels in the thymus, spleen and lymph nodes ([Figure 1a](#F1){ref-type="fig"}). The F~1~ generation of the *Rev1* Tg T5 line was inter-crossbred to yield a Mendelian distribution of transgenic *Rev1 Wt* (*Tg−/Tg−*)*, Tg+/Tg− and Tg+/Tg+* progeny. Pups homozygous (*Tg+/Tg+*) for the *Rev1* transgene were selected for establishment of the colony designated as *Rev1* Tg (Homo), whereas hemizygous (*Tg+/Tg−*) pups were used to establish the *Rev1* Tg (Hemi) colony. MNU causes intestinal tumors in mice ([@CIT0038]), making intestinal adenomas an attractive model in which to study MNU tumorigenesis. Expression of *Rev1* in the small intestine was approximately twice as high in *Rev1* Tg (Homo) as in *Rev1* Tg (Hemi) mice ([Figure 1b](#F1){ref-type="fig"}), confirming that intestinal adenomas were a suitable model for MNU tumorigenesis in *Rev1* Tg mice. *Rev1* Tg (Homo) and *Rev1* Tg (Hemi) mice were used in subsequent experiments to determine whether overexpression of Rev1 could contribute to small intestine tumorigenesis.

![MNU-induced small intestinal tumorigenesis in *Rev1* Tg mice. (**a**) *Rev1* expression levels of wild-type and *Rev1* Tg (Hemi) male mice were measured by semi-quantitative RT-PCR in indicated tissues. *Gapdh* was used as a loading control. (**b**) Relative *Rev1* expression level in small intestines. Significant differences were observed between Wt and *Rev1* Tg (Hemi) mice (*P* = 0.046), and between Wt and *Rev1* Tg (Homo) mice (*P* = 0.0008). (**c**) Survival curves of wild-type (Wt), *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) male mice \[Wt; black line, *Rev1* Tg (Hemi); blue line, and *Rev1* Tg (Homo); red line\] after repeated intraperitoneal injection of MNU (2 × 50 mg/kg of body weight at 6 and 7 weeks of age). Significant differences were observed between Wt and *Rev1* Tg (Hemi) mice (*P* = 0.0059), and between Wt and *Rev1* Tg (Homo) mice (*P* = 0.0001). (**d**) Numbers of adenomas per mouse in Wt (gray), Hemi (blue) and Homo (red) mice. Each circle indicates the result from each mouse.](bgw20801){#F1}

Accelerated MNU-induced intestinal tumorigenesis in Rev1 Tg mice {#s15}
----------------------------------------------------------------

To determine whether overexpression of Rev1 influences spontaneous tumor initiation and progression, we monitored cohorts of Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice over their lifespan (\>2 years). No significant effect on overall survival or tumor incidence was observed in the Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice, suggesting that overexpression of Rev1 by itself is not sufficient to stimulate tumorigenesis (data not shown).

To determine the effect of the *Rev1* transgene on tumorigenesis induced by MNU, we monitored MNU-treated *Rev1* Tg (Homo), *Rev1* Tg (Hemi) and Wt males until they became moribund. As shown in [Figure 1c](#F1){ref-type="fig"}, the lifespans of MNU-treated *Rev1* Tg (Homo) and *Rev1* Tg (Hemi) mice were slightly but significantly shorter than those of Wt mice treated with a similar dose of MNU. Mice were sacrificed after they became moribund, and adenomas in the intestine were counted and measured. The average number of intestinal adenomas after MNU treatment, as well as the mean adenoma diameter, increased in the following order: Wt mice, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo), in accordance with the *Rev1* expression level ([Table 1](#T1){ref-type="fig"}; [Figure 1c](#F1){ref-type="fig"} and [d](#F1){ref-type="fig"}). These observations indicate that the development of intestinal adenomas after MNU treatment was accelerated by Rev1 overexpression in proportion to the Rev1 expression level. By contrast, metastatic invasion of the intestinal adenocarcinoma, as determined by histologic examination, did not differ significantly among the three groups, although the *Rev1* Tg (Homo) and (Hemi) mice exhibited slightly higher incidences of adenocarcinoma than Wt mice ([Table 1](#T1){ref-type="fig"}). Thymic lymphomas were also detected after MNU treatment, and *Rev1* overexpression was associated with earlier onset and higher incidence of this malignancy (Supplementary Table 1, available at *Carcinogenesis* Online).

![Comparison of tumor number, tumor size and adenocarcinoma incidence](bgw208t01){#T1}

Given that development of intestinal adenoma causes anemia ([@CIT0039]), we also measured the Hgb concentration in peripheral blood (Supplementary Figure 2, available at *Carcinogenesis* Online). Since both number and size of adenomas contribute to the onset, incidence and severity of anemia, the parameter 'total adenoma area, mm^2^' was calculated for each animal as the sum of the areas of all adenomas. A negative correlation was observed between the total adenoma area and Hgb level (Supplementary Figure 2c, available at *Carcinogenesis* Online). The average Hgb level decreased in the following order: Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo), in accordance with intestinal adenoma number and size (Supplementary Figure 2a, available at *Carcinogenesis* Online). Mice with anemia (Hgb level \< 5g/dl) were detected much earlier among *Rev1* Tg (Homo) and *Rev1* Tg (Hemi) compared with Wt mice, and the incidence of anemia increased in the following order: Wt mice, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) (Supplementary Figure 2b, available at *Carcinogenesis* Online).

Rev1 overexpression accelerates both initiation and progression of MNU-induced intestinal tumors in an expression level-dependent manner {#s16}
----------------------------------------------------------------------------------------------------------------------------------------

To assess the role of overexpressed Rev1 in the development of intestinal tumors, *Rev1* Tg (Homo), *Rev1* Tg (Hemi) and Wt mice were sacrificed and examined 1 or 2 months after MNU treatment. As shown in [Figure 2a](#F2){ref-type="fig"} and [b](#F2){ref-type="fig"}, the number of adenomas increased in the following order: Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo). Intestines of *Rev1* Tg (Homo) mice contained significantly more tumors than those of *Rev1* Tg (Hemi) and Wt mice 1 month after MNU treatment, suggesting that Rev1 overexpression accelerates the initiation of tumorigenesis. The difference in tumor number between *Rev1* Tg (Homo) mice and *Rev1* Tg (Hemi) or Wt mice was less pronounced at the 2-month time point due to a saturation effect in *Rev1* Tg (Homo) mice. Rev1 Tg (Hemi) mice exhibited an intermediate phenotype at the 2-month time-point only ([Figure 2b](#F2){ref-type="fig"} and Supplementary Figure 3 and Table 2, available at *Carcinogenesis* Online). No significant difference between Rev1 Tg (Hemi) and Wt mice were present at the 1-month time-point. This observation indicates that the relationship between tumor induction and level of Rev1 expression may not be linear in the first weeks after MNU treatment. Like tumor number, average adenoma diameter increased in the following order: Wt, *Rev1* Tg (Hemi), *Rev1* Tg (Homo). No significant differences were observed at the 1-month time point; however, 2 months after treatment, adenomas in *Rev1* Tg (Homo) mice were significantly larger than those in Wt and *Rev1* Tg (Hemi) mice ([Figure 2c](#F2){ref-type="fig"}; Supplementary Figure 4 and Table 2, available at *Carcinogenesis* Online). These results imply that Rev1 overexpression accelerates both initiation and progression of tumor formation after MNU treatment.

![Initiation and progression of tumor formation 1 and 2 months after MNU treatment. (**a**) Images of intestines from Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice 1 or 2 months after MNU treatment. Magnification: ×10. Arrows indicate adenomas. (**b**) Numbers of adenoma tumors in the intestinal tracts of Wt and *Rev1* Tg mice. Each circle indicates the result from one mouse \[Wt; white circle, *Rev1* Tg (Hemi); gray circle, and *Rev1* Tg (Homo); black circle\]. *P* = 0.018 was calculated by the *t*-test. (**c**) Histogram of intestinal adenoma tumor size in Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice after MNU treatment. In each histogram, the number of adenomas for each size interval is presented as average from the mice used. In all cases five mice were used, with the exception of *Rev1* Tg (Hemi) at 2 months, where four mice were used due to technical error.](bgw20802){#F2}

Rev1 overexpression accelerates mutagenesis, as well as tumorigenesis, after MNU treatment {#s17}
------------------------------------------------------------------------------------------

To determine the mechanism by which Rev1 overexpression promotes MNU-induced carcinogenesis, as well as its effect on mutagenesis, we characterized *Ctnnb1* (β-catenin) mutations by sequencing *Ctnnb1* exon 3. *Ctnnb1* exon 3 encodes the GSK-3β phosphorylation consensus motif, which plays an important role in the stability and function of its protein. The mutant sequences are summarized in [Table 2](#T2){ref-type="table"}. The mutation frequency in the *Ctnnb1* gene exon 3 was highest in *Rev1* Tg (Homo), followed by *Rev1* Tg (Hemi) and Wt ([Table 2](#T2){ref-type="table"}).

###### 

Mutation frequency and patterns in exon 3 of the *Ctnnb1* gene in MNU-induced intestinal adenomas

                                                       Wt   *Rev* 1 Tg (Hemi)   *Rev1* Tg (Homo)                 
  ------------------ ------- ------------------------- ---- ------------------- ------------------ -------- ---- --------
                     Codon   Base change               No   \%                  No                 \%       No   \%
                     32      [G]{.ul}AT → [A]{.ul}AT   1    (2.8)               3                  (15.8)   7    (19.4)
                     33      T[C]{.ul}T → T[T]{.ul}T   1    (2.8)               0                  (0.0)    1    (2.8)
  Mutation pattern   34      G[G]{.ul}A → G[A]{.ul}A   10   (27.8)              5                  (26.3)   16   (44.4)
                     37      T[C]{.ul}T → T[T]{.ul}T   1    (2.8)               0                  (0.0)    2    (5.6)
                     41      A[C]{.ul}C → A[T]{.ul}C   10   (27.8)              6                  (31.6)   6    (16.7)

All mutation G:C to A:T.

\*Significantly different from the value in Wt mice *P* = 0.026.

All of the mutations detected in *Ctnnb1* exon 3 were located in codons 32, 33, 34, 37 and 41 ([Table 2](#T2){ref-type="table"}). Mutations in codons 34 and 41 of *Ctnnb1* were previously identified as hotspots for chemically induced adenoma in mouse ([@CIT0040]), but the mutations at codon 32 might represent a mutation specific to adenomas in *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice. Furthermore, to analyze the MNU-induced MF *in vivo*, we performed TCR mutant assays in splenocytes isolated from Wt and *Rev1* Tg (Homo) mice. Even though TCR mutant frequency in splenocytes is expected to be closely associated to thymic lymphoma incidence and is not directly relevant to initiation of intestinal adenoma, the test was used as a general indicator of *in vivo* mutagenicity. Overexpression of Rev1 resulted in MNU-induced TCR mutant frequencies much higher than that in the control (i.e., Wt) (Supplementary Figure 5, available at *Carcinogenesis* Online).

These observations strongly suggest that Rev1 overexpression leads to elevated mutagenesis, which may accelerate the development of intestinal adenomas.

Rev1 overexpression resulted in reduced apoptosis in the intestinal crypts of Rev1 Tg (Hemi) and (Homo) mice after MNU treatment {#s18}
--------------------------------------------------------------------------------------------------------------------------------

To explore the mechanism by which Rev1 overexpression drives stimulation of MNU-induced adenoma formation in the small intestine, we analyzed the prevalence of apoptosis in the intestinal crypt compartment following exposure to MNU. Apoptotic cells were identified using morphological criteria, including cytoplasmic shrinkage, chromatin condensation, and nuclear fragmentation ([Figure 3a](#F3){ref-type="fig"}). Crypt compartments of Wt and *Rev1* Tg (Homo) mice without MNU treatment contained similar numbers of apoptotic cells. However, MNU induced a measurable increase in intestinal apoptosis, with peak induction at 6 h after treatment; moreover, induction was much more pronounced in Wt than in *Rev1* Tg (Homo) mice ([Figure 3b](#F3){ref-type="fig"}). The frequency of apoptosis 6 h after MNU treatment decreased in the following order: Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo), in accordance with the Rev1 expression level ([Figure 3c](#F3){ref-type="fig"}). Analysis of Bcl2 and Bax expression confirmed that MNU-induced apoptotic signaling was lower in *Rev1* Tg (Homo) than in Wt mice (Supplementary Figure 6, available at *Carcinogenesis* Online). These findings suggest that Rev1 controls resistance to apoptosis in the intestinal crypt epithelium after MNU treatment, in proportion to the Rev1 expression level, and that resistance to MNU-induced apoptosis might cause accumulation of mutated intestinal cells.

![Apoptotic response in the intestinal crypts of Wt and Rev1 Tg mice after MNU treatment. (**a**) Hematoxylin and eosin staining of Wt and Rev1 Tg (Homo) mice intestines. Asterisks represent apoptotic cells. Magnification, ×200. (**b**) Number of apoptotic bodies per 50 half-crypts in Wt and *Rev1* Tg (Homo) mice at the indicated time points after MNU treatment (Wt, open circles; and *Rev1* Tg (Homo), closed circles). Each data point represents the mean and standard deviation from three mice. The rate of apoptosis at 6 h differed significantly (*P* = 0.002) between Wt and *Rev1* Tg (Homo) mice. (**c**) Prevalence of apoptotic bodies per 50 half-crypts in Wt, *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice at 6 h after MNU treatment \[Wt, white bars; *Rev1* Tg (Hemi), gray bars; and *Rev1* Tg (Homo), dark gray bars\]. Each bar represents the mean and standard deviation from three mice. The rates of apoptosis differed significantly between Wt and *Rev1* Tg (Hemi) mice and between *Rev1* Tg (Hemi) and *Rev1* Tg (Homo) mice (*P* = 0.017 and *P* = 0.002, respectively).](bgw20803){#F3}

hREV1 overexpression is associated with elevated tolerance to DNA damage with a concomitant increase in mutation frequency {#s19}
--------------------------------------------------------------------------------------------------------------------------

To assess the effects of Rev1 overexpression on cellular responses to MNU-induced DNA damage, we transfected the human HT1080 cell line with a Tet-ON system in which hREV1 is induced by the addition of tetracycline. Forty-eight clones were isolated and expanded, and hREV1 protein levels were determined by Western blotting. As shown in [Figure 4a](#F4){ref-type="fig"} and Supplementary Figure 7a, available at *Carcinogenesis* Online, two clones, HT1080-6TR-hREV1-C6 and -C7, expressed substantially higher levels of hREV1 than parental untransfected HT1080 cells and HT1080-6TR cells.

![Association between hREV1 expression levels and cytotoxicity and mutagenicity of MNU in HT1080 cell lines. (**a**) hREV1 expression levels in parental HT1080 cells and the HT1080-6TR, -C6 and -C7 sublines, as determined by Western blotting; histone H1 was used as an internal control. Full length plot was exhibited in Supplementary Figure 7a, available at *Carcinogenesis* Online. (**b**) Cytotoxic effects of MNU treatment in the hREV1-overexpressing HT1080-hREV1-C6, -C7 cell lines. Cell survival was determined by colony-formation assays. (**c**) *HPRT* mutation frequency in HT1080-hREV1-C6 cells after MNU treatment. (**d**) hREV1 expression level in HT1080-6TR cells transfected with si-Ctrl or si-hREV1. Full-length plot was exhibited in Supplementary Figure 7b, available at *Carcinogenesis* Online. (**e**) Sensitivity of HT1080-6TR cells transfected with si-Ctrl or si-hREV1 to the cytotoxic effects of MNU treatment. Cell survival was determined by colony-formation assays. (**f**) *HPRT* mutation frequency in HT1080-6TR cells transfected with si-Ctrl or si-hREV1 after MNU treatment.](bgw20804){#F4}

Clonogenic assays were used to determine whether overexpression of hREV1 could modulate cellular sensitivity to MNU. In both HT1080-6TR-hREV1-C6 and -C7, addition of tetracycline caused cells to become resistant to MNU treatment ([Figure 4b](#F4){ref-type="fig"}). Thus, overexpression of hREV1 rendered cells resistant to MNU. Knockdown of hREV1 made cells much more sensitive to MNU than cells treated with control siRNA ([Figure 4d](#F4){ref-type="fig"} and [e](#F4){ref-type="fig"}; Supplementary Figure 7b, available at *Carcinogenesis* Online). Notably, we observed a strong inverse relationship between hREV1 protein levels and cellular sensitivity to MNU exposure.

To determine whether overexpression of hREV1 can affect MNU-induced mutagenesis, we measured mutation frequency in the *HPRT* gene by counting the number of 6-thioguanine-resistant colonies. In the HT1080-6TR-hREV1-C6 cell line, spontaneous mutation frequency did not change significantly as a result of the addition of tetracycline ([Figure 4c](#F4){ref-type="fig"}). However, overexpression of hREV1 increased the level of HPRT mutations following MNU treatment. By contrast, hREV1 knockdown decreased the frequency of MNU-induced mutation in HPRT ([Figure 4f](#F4){ref-type="fig"}). These results indicate that the hREV1 expression level modulates the cytotoxicity and mutagenicity of MNU in HT1080 cells. Furthermore, overexpression of hREV1 lowered the frequency of MNU-induced sister chromatid exchange (SCE) (Supplementary Figure 8, available at *Carcinogenesis* Online).

Discussion {#s20}
==========

This study was the first to demonstrate a causal relationship between Rev1 overexpression *in vivo* and chemically induced mutagenesis and tumorigenesis. Rev1, a member of the Y-family of DNA polymerases that function in translesion DNA synthesis (TLS), is a key factor in error-prone TLS. The deletion and overexpression of Rev1 is responsible for the cytotoxicity and mutagenicity of the various DNA-damaging agents ([@CIT0021],[@CIT0024]). Furthermore, upregulation of hREV1 is associated with the pathogenesis of human glioma ([@CIT0035]). However, the *in vivo* role of Rev1 remains poorly understood. The findings reported here show that Rev1 overexpression causes elevated mutagenesis and tumorigenicity after MNU treatment, in a manner that depends on the Rev1 expression level, and that Rev1 plays a critical role in chemically induced tumorigenesis.

Mutation analyses showed that all mutations characterized in MNU-induced intestinal tumors were G:C-to-A:T transitions. Such transitions might be generated by a *O*^6^-methylguanine (m6G) lesion, the major DNA adduct produced by MNU. Rev1 addresses m6G lesions by inserting C nucleotides opposite such lesions, resulting in error-free repair. Accordingly, it remains unclear which pathway provokes the G:C-to-A:T transition in the context of MNU-induced m6G lesions.

Biochemical and genetic data obtained in yeast show that Pol δ can insert a nucleotide (T more efficiently than C) opposite a m6G lesion site, and that Pol ζ then extends from the inserted nucleotide ([@CIT0041]). The combination of Pol ζ and Pol δ promotes m6G bypass more efficiently than either polymerase alone, and might result in a G:C-to-A:T transition. Rev1 plays a crucial role in the association of Pol ζ with a subunit of Pol δ ([@CIT0042],[@CIT0043]). Furthermore, Rev1 enhances extension by Pol ζ in a nonenzymatic manner ([@CIT0041],[@CIT0044]). These results imply that the overexpression of Rev1 accelerates the activity of the Pol δ--Pol ζ pathway in the presence of m6G lesions, thereby increasing MNU-induced mutagenesis. We observed an MNU-induced mutation in codon 32 of *Ctnnb1* exon 3 at a higher frequency in *Rev1* Tg than in Wt mice. This codon was previously reported as a hotspot in rats, but not in mice, suggesting that it may represent a specific hotspot in *Rev1* Tg mice ([@CIT0040],[@CIT0045]). Thus, when Rev1 is overexpressed, replication of the MNU-induced m6G lesion at codon 32 of *Ctnnb1* exon 3 by Pol δ and Pol ζ is more efficient than error-free translesion DNA synthesis by Rev1 or other polymerases such as Pol η. However, further investigations are required to test this hypothesis.

The results reported here show that overexpressed Rev1 suppresses apoptosis and increases the mutation frequency in the *Ctnnb1* exon 3 region after MNU treatment. The surviving fraction of mutated cells was higher under Rev1 overexpression, resulting in acceleration of carcinogenesis. These observations suggest that both mutagenic TLS and error-free TLS by dCMP insertion are promoted by overexpression of Rev1, allowing completion of stalled replication and inhibition of apoptosis. Consistent with this hypothesis, an increase in hREV1 expression in HT1080 cells increased both MNU resistance and MNU-induced mutagenicity. Furthermore, overexpression of hREV1 lowered the frequency of MNU-induced sister chromatid exchange (SCE) (Supplementary Figure 8, available at *Carcinogenesis* Online). The reduced sensitivity and elevated mutagenicity of MNU in hREV1-overexpressing cells could be attributed to a higher level of error-free and mutagenic TLS. By contrast, suppression of hREV1 expression in HT1080 cells increased MNU cytotoxicity and decreased MNU mutagenicity. Strong associations were observed between these parameters, indicating that the REV1 level modulates MNU cytotoxicity and mutagenicity. Further investigations are needed to clarify the molecular mechanisms underlying Rev1-mediated regulation of apoptosis induced by DNA-damaging agents.

Previous work showed that *Rev1*^*B/B*^ cells, which contain a deletion in the N-terminal BRCT domain of *Rev1*, are sensitive to exogenous DNA-damaging factors and exhibit lower levels of ultraviolet C (UVC)-induced mutagenesis ([@CIT0009]). However, the same study showed that *Rev1*^*B/B*^*XPC*^*KO*^ mice are more vulnerable to skin carcinogenesis than *Xpc*^*KO*^ mice, despite the reduction in mutagenesis due to the *Rev1*^*B/B*^ alleles ([@CIT0046]). The authors hypothesized that this paradoxical phenotype was due to the induction of inflammatory hyperplasia, implying that Rev1 plays a role in tumor promotion. Thus, maintenance of optimal Rev1 levels is important for tumor initiation and promotion, and thereby controls carcinogenesis.

The findings of this study demonstrate the effect of Rev1 overexpression on a mouse model of tumorigenesis. Overexpression of Rev1 promotes mutagenic TLS to safeguard replication on damaged templates at the expense of mutagenesis, thereby accelerating tumorigenesis. Although the mechanisms responsible for hREV1 overexpression in human carcinogenesis are not well understood, control of Rev1 levels is clearly necessary for genomic stability and tumor suppression.

*Rev1* Tg mice represent a promising tool for developing a deeper understanding of the role of Rev1 in tumorigenesis, as well as for elucidating the mechanism of tolerance to anticancer agents used therapeutically.

Supplementary material {#s21}
======================

Supplementary data are available at *Carcinogenesis* online.
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